Lung Adenocarcinoma — Trials

Lung Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 27
Ph III recruiting: 6
Growth YoY: —
Industry share: 13%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05498597	AMT-151 in Patients With Selected Advanced Solid Tumours	unknown	Phase 1	30	Multitude Therapeutics Inc.INDUSTRY	2	Oct 19, 2023	clinicaltrials
NCT05079022	ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas	unknown	Phase 1 / Phase 2	50	Peking University People's HospitalOTHER	1	Oct 15, 2021	clinicaltrials